EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

Call Senior Fellowship (SF)
Programme EDCTP2
Start Date 2017-09-01
End Date 2022-08-31
Project Code TMA2015SF1037
Status Active

Title

Low frequent HIV drug resistant polymorphisms in infants born to HIV sero-positive mothers: implications on response therapy

Host Organisation

Institution Country
Joint Clinical Research Centre Uganda

Current Organisation

Joint Clinical Research Center

Current Job Title

Senior Virologist

Students Supervised

Type Name Title University Start Date End Date
Masters Student Daniel Karara SIGNIFICANCE OF MINORITY HIV-1 X4-TROPIC VARIANTS, HOST CCR5 PROMOTER GENOTYPE IN PREDICTING PAEDIATRIC VIROLOGICAL FAILURE Makerere University 2018 2019
Masters Student Faryad Muwabe EVOLUTION OF LOW-FREQUENT HIV DRUG RESISTANT MUTATIONS IN HIV-1 SEROPOSITIVE INFANTS DURING INTENSIFIED ADHERENCE COUNSELLING Makerere University 2019 2022

Memberships

Role Committee/board Start Date End Date

Education

Institution Degree Year
Case Western Reserve University, United States PhD 2010-05-18
Mbarara University of Science and Technology, Uganda MBChB 1997-08-20

Areas Of Specialisation

Human Immuno-deficiency Virus (HIV)

Grants

Publications

Projects

Fellow:
Immaculate Nankya
Collaborators:
Name Country Institution
Immaculate Nankya Uganda Joint clinical Research Center
Objectives:
1. To determine the prevalence of low-frequency HIV transmitted drug resistant mutations in infants born to HIV-sero positive mothers taking triple combination therapy in the Elimination of Mother to Child Transmission of HIV (EMTCT) program. 2. To evaluate the effect of initiation of triple combination ART to HIV positive infants with low-frequent polymorphisms on subsequent response to therapy over a two year period. 3. To determine co-receptor evolution in mother-infant pairs failing on ART 4. To access socio-economic factors associated with poor adherence to ART in mother infant pairs failing with a viral load greater than 1000 copies/ml. 5. To assess the effectiveness of IAC in mother-infant pairs in mothers and infants whose viral load is greater than 1000 copies/ml on a follow up viral load test 6. To determine the evolution of minority and majority HIV drug resistant variants during the course of IAC in mother-infant pairs
Sites:
Joint Clinical Research Centre, Kampala, Uganda
Study Design:
A randomized open label non-inferiority controlled clinical trial.
Subjects:
HIV sero-positive babies born to HIV positive mothers.
Outcomes:
Primary end point: Detection of a viral load greater than 1000 copies. These patients then based on the regimen they are taking, a drug resistance test will be done and switched to a regimen as dictated by the drug resistance results. Secondary endpoint: Determination of levels of adherence in patients with a detectable viral load greater than 1000 copies/ml.
Start Date:
2017-09-30
End Date:
2022-08-01

Send a Message